Unveiling the benefts of Vitamin D3 with SGLT-2 inhibitors for hypertensive obese obstructive sleep apnea patients
Background Obstructive sleep apnea (OSA) is associated with poorer quality of life (QoL) and increased cardiovascular risks, which may be exacerbated by hypovitaminosis D. Sodium glucose transporter-2 inhibitor (SGLT2i) provides cardiovascular benefts beyond glycemic control. As vitamin D3 and SGLT...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | en |
| Published: |
BioMed Central Ltd.
2025
|
| Subjects: | |
| Online Access: | http://ir.unimas.my/id/eprint/47737/1/Unveiling%20the%20benefits.pdf http://ir.unimas.my/id/eprint/47737/ https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-025-06312-w#:~:text=This%20is%20the%20first%20study,QoL%20in%20this%20patient%20population. https://doi.org/10.1186/s12967-025-06312-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background Obstructive sleep apnea (OSA) is associated with poorer quality of life (QoL) and increased cardiovascular risks, which may be exacerbated by hypovitaminosis D. Sodium glucose transporter-2 inhibitor (SGLT2i) provides
cardiovascular benefts beyond glycemic control. As vitamin D3 and SGLT2i act through diferent pathways with similar mechanisms in improving cardio-metabolic health, this study aimed to investigate the synergistic efects of this
combination therapy in improving these parameters and QoL in hypertensive obese OSA patients.
Methods Patients who fulflled the study criteria were randomized to receive: (i) Dapaglifozin, (ii) vitamin D3, (iii) Dapaglifozin plus vitamin D3, or (iv) no treatment, for 16 weeks. The parameters evaluated included anthropometric measurements, uric acid, HbA1c, lipid profle, steatotic liver disease grade, plasma aldosterone concentration, plasma renin concentration, ultrasound fow-mediated dilatation of brachial artery, hsCRP, heart rate variability (HRV), Epworth Sleepiness Scale (ESS), and QoL scores.
Results A total of 163 patients were recruited and 153 completed the study. The combination of vitamin D3
and Dapaglifozin treatment led to signifcant improvements in metabolic parameters and nocturnal heart rates,
and prevented deterioration of HRV, with healthier HRV at the end of study visit compared to the control group. Only
the combination group exhibited improvements in both ESS and QoL scores.
Conclusions This is the frst study to demonstrate benefcial efects of combining vitamin D3 and SGLT2i in cardiometabolic outcomes and QoL in hypertensive obese OSA patients. These fndings highlight the potential of this combination therapy in addressing the cardio-metabolic challenges and QoL in this patient population.
Trials registration NCT06690723. Registered 10 October 2024—Retrospectively registered, https://register.clinicaltr
ials.gov/prs/beta/studies/S000EWGF00000085/recordSummary |
|---|